Happy woman playing pickleball

使用 Light Adjustable Lens™ 先體驗再確定你的視力

如果你正在閱讀這篇文章,你很可能正在考慮使用 Light Adjustable Lens (LAL™),這是一種用於白內障手術的新型晶體植入體,可讓你掌控自己的視力。使用 Light Adjustable Lens,讓你預覽手術後的視力,並根據自己的生活方式進行微調,以確保達到最佳效果。

手術後,你可以先體驗新的視力,然後醫生會根據你的生活方式和視力需求來調整晶體度數。在晶體度數永久鎖定之前,此過程最多可重複三次。在你開始這段療程時,請使用本網誌作為指南,來瞭解定制視力的過程。

遵循你的眼藥水方案

手術後,你的眼科護理團隊可能會開不同類型的眼藥水處方(如下所述),以幫助眼睛恢復並減輕炎症。為了達到最佳效果,請務必仔細遵照醫囑。

  • 處方眼藥水:這類眼藥水有助於預防感染並促進眼睛恢復。醫生會為你的眼睛提供具體的治療方案,請務必遵照醫生的指導。
  • 人工淚液:可能會建議使用這類人工淚液,以保持眼睛的水分和舒適度。你的眼科醫療服務提供者將為你提供建議。

在日常生活情境中測試你的視力

在進行日常活動時,請注意雙眼的視力表現。避免比較雙眼的視力,因為雙眼本應協調工作。以下是一些有用的提示:

  • 家和工作場所評估你的視力。嘗試閱讀書籍或螢幕上的文字。
  • 在你喜愛的活動和愛好中測試你的視力。嘗試閱讀棋盤遊戲的規則,觀看帶字幕的電影,以及觀察光線和距離對視力的影響。
  • 寫日記記錄你的視力體驗。
  • 記下任何變化或疑慮,以便與你的眼科護理團隊討論。

獲得清晰的視力不是一朝一夕的事。可能需要幾次就診來微調效果。請記住,你的新晶體與你的天然晶體不同,所以請給眼睛一些時間來適應。

你的視力,由你掌控。

個人化你的視力效果是一個合作的過程,需要你與醫生積極配合,在光療之間監測你的視力,並遵照你的處方眼藥水方案。遵循這些步驟將有助於確保你的眼睛正常癒合,達到最佳視力效果。優化體驗的關鍵包括以下幾點:

  • 觀察你的視力在不同情況下(家庭、工作、業餘愛好等)的反應。
  • 追蹤你的視力進展情況,並與你的眼科護理專業人士交流任何疑慮。
  • 保持耐心。獲得最佳視力需要時間,但這項投資將為你帶來更清晰、個人化的終身視力

如需瞭解有關 Light Adjustable Lens 的更多資訊,請造訪我們的常見問題頁面。如果你想與專業人士交流,在我們的網站上尋找醫生

最新文章

白內障手術與乾眼症:須知事項

固定式與可調節型晶體設計:瞭解哪種設計適合你

瞭解白內障手術:讓你的視力從此更清晰

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The Light Adjustable Lens provides optimized vision for patient satisfaction.2

Light Adjustable Lens patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the Light Adjustable Lens is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1